Background: Patient recruitment for randomized clinical trials is often challenging, especially when the alternatives being studied may require significant changes or have large consequences for the patient. We describe our experience recruiting patients for a clinical trial comparing the Comprehensive Care Program (CCP), a care delivery model in which physicians focus their practice on caring [...]

Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects at least 20% of the general population. There is a significant predominance of IBS in females, with a female: male ratio of 2:1, especially in western countries. In contrary Eastern countries, some studies report that men with IBS are 4 times more affected [...]

Background: Antibiotics used to treat Clostridioides difficile infection (CDI) can predispose patients to recurrent CDI (rCDI). Gut microbiome restoration by fecal microbiota transplantation is recommended by multiple guidelines after ≥2 episodes of rCDI, with no guideline-recommended options to restore the microbiome earlier in the course of CDI. RBX2660 is a standardized, microbiota-based live biotherapeutic being [...]

Background: Clostridioides difficile is an opportunistic pathogen that causes an estimated 500,000 infections per year in the United States. RBX2660, a standardized, microbiota-based live biotherapeutic, is being investigated as a treatment option for recurrent C. difficile infection (rCDI). RBX2660 has demonstrated consistent tolerability and efficacy in reducing rCDI across 6 clinical studies. We present a [...]

Background: Low serum concentrations of tetracycline antibiotics may raise concerns on their efficacy in patients with secondary bacteremia, especially in comorbid patients and in those with higher acuity of illness. Omadacycline (OMC), an aminomethylcycline antibiotic, showed non-inferiority to linezolid (LZD) in two acute bacterial skin and skin structure infections (ABSSSI) studies (Omadacycline in Acute Skin [...]

Background: Racial minorities are underrepresented in cancer-related clinical trials. One commonly recognized contributor to this is medical mistrust. Methods: This study used data from the 2020 National Cancer Institute’s Health Information National Trends Survey (HINTS), a cross-sectional, nationally representative sample of 3865 participants. We sought to determine the prevalence of medical mistrust and its impact [...]